Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Development of Pulmonary Arteriovenous Malformations During Trastuzumab Emtansine Therapy for HER2-Positive Breast Cancer
Soto, Jose Soto , Delgado, Julio

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1929-A1929

10.1164/ajrccm.2025.211.abstracts.a1929 Get It

Abstract Introduction: Trastuzumab emtansine (T-DM1) is a standard therapeutic agent for advanced stages of HER2-positive breast cancer, known to improve survival rates. However, it is associated with side effects including fatigue, anemia, and mild-to-moderate bleeding. We present a rare case of pulmonary arteriovenous malformations (PAVMs) potentially linked to T-DM1 therapy, with clinical manifestations resembling hereditary hemorrhagic telangiectasia (HHT). Case Presentation: A 57-year-old female presented with chronic hypoxia on 3 L/min nasal oxygen. Her history included two years of worsening exertional dyspnea and hypoxemia during T-DM1 therapy for HER2-positive breast cancer, diagnosed 10 years earlier. She underwent bilateral mastectomy and was treated with T-DM1 and anastrozole. Echocardiography suggested a right-to-left shunt, while right heart catheterization excluded pulmonary hypertension. Subsequent CT angiography revealed small peripheral PAVMs, confirmed by Tc-99m MAA scintigraphy with a 30% right-to-left shunt. Lab results showed PaO2 at 52 mmHg, HCO3 at 20.3 mmol/L, O2 saturation at 86.4%, and PCO2 at 31 mmHg. Pulmonary function tests indicated restrictive lung volumes and severe diffusion impairment (FVC: 2.66 L, FEV1: 2.06 L, FEV1/FVC: 77.5%, TLC: 3.99 L, DLCO-SB: 20.7% predicted). Following discontinuation of T-DM1, patient experienced slight improvement in telangiectasias and dyspnea over three months but continued to require 10-15 L/min of oxygen during exertion. Arterial blood gas analysis showed a PaO2 of 56.4 mmHg, HCO3 of 20.7 mmol/L, resting O2 saturation of 88.4%, PCO2 of 26.8 mmHg, and PaO2 of 180.9 mmHg on 100% oxygen via a non-rebreather mask, indicating a persistent right-to-left shunt. Discussion: Arteriovenous malformations (AVMs) are abnormal artery-vein connections linked to HHT, with PAVMs present in 80-90% of HHT cases, leading to right-to-left shunts. This patient's prolonged T-DM1 therapy appears associated with PAVMs and HHT-like symptoms. While T-DM1 has been linked to pulmonary and portal hypertension, as well as cerebral AVMs, this is the first report associating it with PAVMs, possibly through disruption of endothelial function and HHT pathways like ALK1 and ENG. Diagnosing PAVMs can be challenging due to their often-asymptomatic nature; however, in this case, they were identified through repeated CT imaging and Tc-99m MAA scintigraphy. Embolization, a typical intervention for PAVMs, was not feasible due to the small size of the malformations. The patient's condition improved after discontinuing T-DM1, suggesting a potential link between the drug and PAVMs. Understanding the mechanisms by which T-DM1 induces vascular abnormalities is crucial for developing targeted interventions and improving patient outcomes.
Abemaciclib Induced Drug Pneumonitis
Mokahal, Ali El , Hussein, S.H., Farah, Wigdan

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1899-A1899

10.1164/ajrccm.2025.211.abstracts.a1899 Get It

Abstract Introduction Abemaciclib is a selective CDK4/6 inhibitor approved for metastatic breast cancer. We report the clinical course of Abemaciclib-induced pneumonitis, emphasizing the need for vigilant monitioring for interstitial lung disease (ILD) in patients receiving this therapy. Case description An 85-year-old woman with a history of HR-positive, HER2-negative breast cancer, Atrial fibrillation, and stage 3 chronic kidney disease presented with cough and weakness and a temperature of 100.1° F. She was hypoxic, requiring 4 liters of oxygen, she was in atrial fibrillation with a heart rate of 114, and blood pressure was 98/46. Laboratory testing showed an NT-Pro BNP: 5768, leukocytes: 2900 with 420 lymphocytes and an acutely elevated creatinine of 1.83 mg/dL (basline 1.3-1.4 mg/dL). Her CRP was 245 mg/L. Chest X-Ray revealed diffuse interstitial opacities. She was treated for pneumonia with cefepime and azithromycin, volume resuscitation and subsequent diuresis. However, her hypoxia continued to worsen. A chest CTA excluded pulmonary embolism but revealed progression of diffuse ground-glass and reticular opacities with a basilar apical gradient and enlarged mediastinal and hilar lymph nodes. An echocardiogram showed a mildly enlarged right ventricle and elevated right ventricular systolic pressure of 60. Subsequent infectious and autoimmune workups were inconclusive, bronchoscopy evaluation was deferred due worsening respiratory status. Given the concern for drug induced pneumonitis she was started on a steroid taper with 2 mgs/kg of IV Methylprednisolone. Over two weeks, her condition improved, and she was discharged without supplemental oxygen. Discussion Pneumonitis is a rare adverse effect of abemaciclib likely driven from CDK4/6 inhibitors. In a safety analysis of the MONARCH 2&3 trials, the incidence of pneumonitis was 2-5%, compared to 0.4-0.6% in the placebo arms. In these trials, two and one patients died of pneumonitis respectively. Our patient received abemaciclib for 2 years and 10 months, during which her follow up PET CT scan few months after treatment initiation demonstrated a new ground-glass and reticular opacities that continued to worsen on subsequent surveillance PET CT scans with significant progression noted on admission CT. In the absence of other contributing factors, our patient was diagnosed with Grade 3 lung toxicity, and abemaciclib was discontinued. The progression of her imaging before admission highlights the need for close monitoring for interstitial lung disease in patients receiving abemaciclib, to determine if dose reduction or treatment adjustment is warranted.
Abemaciclib-induced Pneumonitis
Kahn-Pascual, Y., Hafdahl, Luke

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1886-A1886

10.1164/ajrccm.2025.211.abstracts.a1886 Get It

Abstract Introduction: Abemaciclib is a cyclin-dependant kinase 4/6 inhibitor used to treat HR+/HER2- advanced or metastatic breast cancer with disease progression following endocrine or chemotherapy. In 2023, the FDA expanded its indication alongside endocrine therapy for early HR+/HER2- breast cancer with high risk of recurrence. We present a case of Abemaciclib induced pneumonitis to raise awareness of this rare complication in a relatively new treatment with growing use. Case Presentation: An 85 year old female with HFpEF, atrial fibrillation on Rivaroxaban and metastatic breast adenocarcinoma on Letrozole/Abemaciclib for three years, was admitted with non-productive cough, dyspnea and low-grade fever. On initial evaluation she was hypoxemic requiring 4L/min of oxygen, and in atrial fibrillation at 140bpm. Chest x-ray showed bilateral airspace and interstitial opacities with vascular congestion. Respiratory viral panel was negative, and labs showed lymphopenia, elevated BNP (5768pg/mL), elevated CRP (245mg/L) and ESR (135mm/h). Ceftriaxone and Azithromycin was started, and Letrozole/Abemaciclib held. After 72h, despite antibiotics, rate control and diuresis, her hypoxemia persisted. On reviewing prior PET-CT scans from her oncological monitoring, early mosaic attenuation in both lungs was noted. Chest CT was obtained and revealed diffuse ground-glass and reticular opacities with basilar apical gradient. Due to fragile respiratory status, bronchoscopy was deferred and induced-sputum obtained. Extensive testing was negative including autoimmune studies, serum beta-D-glucan and galactomannan, Histoplasma/Blastomyces, Pneumocystis jirovecii, AFB stain, sputum and blood cultures. With a negative workup and chest CT suggesting non-infectious pneumonitis, she was treated with Methylprednisolone for a Grade 4 Drug-Induced Interstitial Lung Disease (DIILD). Treatment resulted in rapid improvements, and she was eventually weaned off oxygen. She was discharged with prednisone taper and outpatient Pulmonology follow up with repeat CT in 6-8 weeks. Discussion: Abemaciclib is associated with severe, potentially fatal DIILD. In clinical trials MONARCH 1-3, 3.4% of patients had pneumonitis of any grade, 0.6% had Grade 3-4, and in 0.4% it was fatal. Many agencies including the FDA and MHRA (United Kingdom) released post-marketing surveillance warnings to raise awareness of this toxicity. Our case highlights an important differential when autoimmune or microbiological workup is negative, and the patient is not improving despite diuresis and antibiotics. PET-CT imaging is frequently done in these patients for oncological monitoring, and re-review of these prior scans during acute admissions can evaluate for early evidence of non-infectious pneumonitis. Prompt recognition, discontinuation of Abemaciclib and early steroid therapy can prevent progression to severe respiratory failure or death.
Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation
Kommaraju, K., Alsharif, Muath, Saddoughi, Sahar A. , Pennington, Kelly M. , Scott, J.P.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1877-A1877

10.1164/ajrccm.2025.211.abstracts.a1877 Get It

Abstract Introduction: Calcineurin inhibitor (CNI) nephrotoxicity is a common complication following lung transplant. This is usually treated with dose reduction of CNI, addition of mammalian target of rapamycin inhibitor (mTORi), or rarely, CNI withdrawal which poses the risk of acute and chronic lung allograft rejection. Complete CNI withdrawal and transition to a mTORi based regimen for renal protection is scarcely described in literature with mixed results. Methods: We performed a single center, retrospective chart review of adult lung transplant recipients from January 2010-December 2022 to identify those who underwent complete CNI withdrawal and transition to a mTORi based immunosuppression regimen. Dual organ transplants and external transplant surgeries were excluded. Demographics, and clinical information on immunosuppressive regimens, renal function, rejection episodes, and outcomes were collected. This study was approved by the Mayo Clinic Institutional Review Board. Descriptive statistics were employed. Data is presented as N (%) or median (IQR). Results: A total of 52 patients who underwent CNI withdrawal were identified, and 38 patients (73.1%) were transitioned to a mTORi based regimen for renal failure. The median age at transplant was 59.1 years (IQR 54.2-63.3) and 57.9% were male. The most common transplant indication was pulmonary fibrosis (N = 21, 55.3%). No patients had pre-transplant chronic kidney disease stage 3 or higher. The median length of time from transplant to CNI withdrawal was 13.0 months (IQR 10.0-28.6). Most patients (N = 35 out of 38, 92%) discontinued mTORi and returned to a CNI based regimen after a median duration of use of 4.5 months (IQR 2.4-12.0) for an upcoming procedure/facilitate wound healing (N = 7, 20%), hypervolemia (N =7, 20%), death (N = 6, 17%), lung toxicity (N = 5, 14%), or worsening allograft function (N=5, 14%). Five patients (13.2%) developed ≥ A2 acute cellular rejection. Ten patients (26.3%) developed chronic lung allograft dysfunction. There was no change in creatinine at baseline (just prior to CNI withdrawal) compared to 12 (+/- 3) months after mTORi initiation (p = 0.36). Thirteen patients required dialysis (34.2%), four patients received renal transplants (10.5%), and 1 patient died on the renal transplant waitlist. Conclusions: Our case series demonstrates complete CNI withdrawal and transition to mTORi regimen is associated with short duration of therapy for most patients due to side effects and no change in creatinine one year after transition.
A Retrospective Study Identifying Factors Associated With Long-term Survival in Lung Transplant Recipients: A Focus on Psychosocial Wellbeing and Social Determinants of Health
Kennedy, Cassie C. , Saddoughi, Sahar A. , Yadav, Hemang , Pennington, Kelly M. , Kennedy, Cassie C , Huang, E.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1874-A1874

10.1164/ajrccm.2025.211.abstracts.a1874 Get It

Abstract RATIONALE: Long-term survival after lung transplantation is challenging, with limited research on risk and protective factors. Clinical factors such as younger age, female sex, fewer acute rejection hospitalizations, and double lung transplants are associated with better outcomes. However, the role of psychosocial health and socioeconomic status (SES) remains underexplored. This study aimed to assess the influence of pre-transplant psychosocial health and SES on long-term survival in adult lung transplant recipients. METHODS: We conducted a single-center, retrospective case-control study using the Mayo Clinic Rochester lung transplant registry. Cases (survivors ≥ 6 years) and controls (survivors <6 years) were matched by transplant date (+/- 5 years) and indication for transplant, resulting in 190 subjects (63 cases, 127 controls). We assessed the impact of pre-transplant psychosocial health and SES on long-term survival using initial PACT scores (<2), the HOUSES index, and the national/state area deprivation index (ADI). Additional factors included proximity to the transplant center, insurance type, marital status, primary caregiver status, and employment status. Statistical analyses used the paired Wilcoxon rank-sum test for continuous variables and McNemar's test for categorical variables, with results reported as median (IQR) or percentages. RESULTS: Donor characteristics (age, sex, smoking history, risk criteria, cause of death) and recipient characteristics (age at transplant, sex, BMI, medical condition, functional status, type of transplant) were similar between cases and controls, with no statistically significant differences (all p>0.05). CMV mismatch, waitlist time, and transplant hospital length of stay were also comparable (all p>0.05). Psychosocial health indicators, including proximity to the transplant center, pre-transplant initial PACT score, insurance type, marital status, primary caregiver, and employment status, did not differ significantly between groups (all p>0.05). The HOUSES index was similar between cases and controls (p=0.179). However, long-term survivors had significantly higher national and state ADI scores than controls (national ADI: p=0.029; state ADI: p=0.019). CONCLUSIONS: Pre-transplant psychosocial health indicators, including proximity to the transplant center, initial PACT score, and caregiver support, did not differ significantly between long-term lung transplant survivors and those with shorter survival. Although SES measured by the HOUSES index was not associated with long-term survival, higher national and state ADI scores were linked to increased long-term survival, suggesting unique protective factors for patients from socioeconomically deprived areas. These findings highlight the complex role of socioeconomic factors in lung transplant outcomes and underscore the need for further research into how specific socioeconomic and environmental factors influence long-term survival.
Impact of Pre-transplant Mechanical Ventilation Duration on Early Post-heart Transplant Outcomes: A Retrospective Analysis
Chaudhary, Ajay Kumar , Bhusal, S. , Karki, Dhan Bahadur , Sanghavi, Devang , SAHAJWANI, JUHI , Chaudhary, S., Karki, D., Bhattacharyya, A., Guru, Pramod

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1867-A1867

10.1164/ajrccm.2025.211.abstracts.a1867 Get It

Abstract Rationale: Mechanical ventilation is frequently required in heart transplant patients to support recovery, but prolonged ventilation may increase the risk of complications and mortality. This study is done to find the impact of pre-transplant ventilation duration on early post-transplant outcomes, including mortality, ICU stay, infection, and respiratory complications. Methods: This retrospective analysis includes 52 heart transplant recipients from Mayo Clinic (2019-2023) who required pre-transplant mechanical ventilation. We analyzed ventilation duration's relationship with ICU and hospital stay, infection rates, respiratory complications, mortality, and baseline demographics. Chi-squared and Mann-Whitney U tests were used to evaluate associations between co-morbidities, ventilation duration, and outcomes. Results: The mean age at transplant was 48.9±14 years. Average ventilation duration was 12.8±14.2 days (Median: 7 days), ICU stay was 24.8± 20.9 days (Median: 15.0 days), and hospital stay was 58±40.8 days (Median: 48 days). Of the patients, 5 (9.6%) did not survive. There was no statistically significant association between mortality and ventilation duration, with a mean duration of 12.7±14.6 days (Median: 7 days) for survivors and 13.6±11.5 days (Median: 21 days) for non-survivors (p>0.05). Patients with infections 23 (44.2%) or respiratory complications 17 (32.7%) had longer ventilation durations (mean 16.3±17.8 days, Median: 9 and 10 days, respectively) compared to those without complications (mean 10±10.2 days, Median: 6 and 5 days, p>0.05). Infection was associated with extended ICU stays (mean 27.5±22.3 days, Median: 18 days with infection vs. 22.7±19.9 days, Median: 15 days without infection). None of the individual co-morbidities (diabetes, hypertension, stroke, chronic kidney disease) significantly impacted mortality or ventilation duration (p > 0.05). Conclusions: Prolonged ventilation is associated with increased rates of infections and respiratory complications but not with mortality in this cohort. Although co-morbidities did not significantly impact ventilation duration or mortality, infection remains a critical factor related to extended ICU stay. Future research should explore preventative strategies for infections in ventilated heart transplant recipients to improve outcomes.
Role of Postoperative Hemodynamics and Clinical Parameters in Predicting Mortality and Complications Post-heart Transplant
Bhusal, S. , Chaudhary, Ajay Kumar , Karki, Dhan Bahadur , SAHAJWANI, JUHI , Patel, Parag J. , Chaudhary, S., Guru, Pramod , Karki, D., Patel, P.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1866-A1866

10.1164/ajrccm.2025.211.abstracts.a1866 Get It

Abstract Rationale: Early management after heart transplantation is essential for survival and quality of life, but we lack data on how initial clinical measures might predict patient outcomes. This study investigates whether early postoperative hemodynamic and clinical parameters can predict 1-year mortality and complications. Methods: We conducted a retrospective study of 550 heart transplant patients treated at the Mayo Clinic from 2019 to 2023. Demographic, hemodynamic, and clinical data, including Central Venous Pressure (CVP), Pulmonary Arterial Pressure (PAP), cardiac index, Pulmonary Artery Pulsatility Index (PaPi), blood pressure, heart rate, and Vasoactive-Inotropic Score (VIS), were collected. Key outcomes included 1-year mortality, Intensive Care Unit (ICU) and hospital stay durations, and complications such as respiratory issues and Acute Kidney Injury (AKI). Patients were divided into quartiles based on VIS scores to compare clinical outcomes. Logistic regression assessed how each parameter predicted 1-year mortality. Results: The patients’ mean age was 53.3±13.1 years, with 391 (71.1%) male and an average Body Mass Index (BMI) of 27.5±4.9. The median ICU stay was 9 days (Interquartile Range [IQR]: 4-22.8), and the median hospital stay was 35 days (IQR: 17-57.8). Within one year, 28 (5.1%) patients experienced mortality and ICU readmission occurred in 52 (9.5%) patients. Higher VIS quartiles were associated with worse outcomes. Logistic regression revealed three significant predictors of 1-year mortality: higher CVP (p=0.0305) and lower Systolic Blood Pressure (SBP) (p=0.0484) were linked to increased mortality risk, while each unit increase in VIS (p=0.0355) raised mortality odds by 6% (Odds Ratio [OR]: 1.06, 95% Confidence Interval [CI]: 1.004-1.113). Additionally, respiratory complications were seen in 177 (32.2%) patients, and AKI in 407 (74.0%) patients. AKI significantly predicted mortality (OR=2.50, p=0.044), while both ICU readmission (OR=2.98, p<0.001) and AKI (OR=3.49, p<0.001) predicted respiratory complications. Conclusions: Early postoperative hemodynamic and clinical parameters, especially higher VIS scores, are significant indicators of 1-year mortality in heart transplant patients. These findings highlight the importance of early assessment to identify high-risk patients and potentially guide post-transplant management strategies.
Acute Fibrinous and Organizing Pneumonia (AFOP) Demographics, Clinical Presentation, Radiology and Diagnostic Modalities. A Systematic Review of Case Reports
Khan, Ayesha , Khan, Ashraf A. , Lalwani, Anil K. , Platt, Alec B., Yousaf, Zohaib , Khalid, S., Asghar, Muhammad Sohaib

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1820-A1820

10.1164/ajrccm.2025.211.abstracts.a1820 Get It

Abstract Introduction:AFOP is a pattern of lung injury with intra-alveolar fibrin balls and organizing pneumonia. In 2013, the ATS/ERS revised their classification of idiopathic-interstitial-pneumonia to include acute-fibrinous-organizing-pneumonia(AFOP) in their rare histologic patterns. Methods: MEDLINE(PubMed), EMBASE, and Cochrane were searched for AFOP-related case reports/case series. Mesh terms used included (“acute fibrinous and organizing pneumonia” OR AFOP OR “acute fibrinous organizing pneumonia” OR (“acute fibrinous” AND “organizing pneumonia”) OR (“acute fibrinous” AND “organizing pneumonia”). A total of 177 patients were synthesized in these 169 articles, 9 of which were case series and the rest individual case reports. A quality review and data extraction was done on Covidence using a JBI checklist.Results:Mean age of 52.2 +/- 17.4 years with 55% of them were males. The associations were; malignancy (16%), smoking (14%), organ transplant (13%), Hypertension (10%), and use of immunosuppressive agents (6%) were frequent risk factors. Cough (73%), shortness of breath (71%), and fever (61%) were found highly frequent symptoms. Predominant radiological findings were multifocal infiltrates/consolidation (50%) and ground glass appearance (39%). Leukocytosis and inflammatory markers were elevated in most cases. Transbronchial/EBUS (32%), open surgical (29%), imaging-guided (22%), and VATS (14%) were common modes of lung biopsy. Treatment is usually steroids (88%) and antibiotics (69%). Death occurred in 23% of the cases, clinical or radiological improvement was achieved in 69%, while only three recurrences were reported. Most cases are either idiopathic or associated with myelodysplastic syndrome as causative factors reported by authors. DiscussionAFOP presents non-specific symptoms and a community-acquired pneumonia-like clinical picture. Treatment included antibiotics, corticosteroids, and other immunosuppressants with variable outcomes. Discontinuation of suspected drug was the sole treatment strategy reported in some cases. Partial lobectomy/lesion resection was a successful treatment in some instances with localized disease.The survival in AFOP was significantly worse than obliterative bronchiolitis (median time to death 101 vs. 294 days; P = 0.02). A statistically non-significant trend towards higher mortality associated with higher body mass index (BMI) and a long interval between symptom onset and diagnosis of AFOP was reported by Kim et al. in a cohort from South Korea. Conclusion:AFOP being a rare histological pattern of acute lung injury, is a relatively new entity that requires a better clinical and radiologic understanding for the clinical challenge it poses. This systematic review will be able to provide answers to clinicians to think in that direction and manage acute lung injury accordingly.
Pulmonary Alveolar Proteinosis: Clinical Characteristics and Whole Lung Lavage Utilization Trends, a Nationwide Study
Labban, M. El, Eid, Kevin , Zibaoui, Roba El , Eid, K., Ataya, Ali

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1817-A1817

10.1164/ajrccm.2025.211.abstracts.a1817 Get It

Abstract Rationale: Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the accumulation of surfactant in the alveoli, primarily seen in autoimmune PAP (aPAP), which accounts for over 90% of cases. The COVID-19 pandemic has highlighted the potential for viral infections to exacerbate or induce PAP, complicating diagnosis and treatment. Objective: This study aims to provide updated clinical and demographic characteristics of patients with pulmonary alveolar proteinosis (PAP) and to analyze trends in the use of whole lung lavage before the COVID-19 pandemic, as well as assess the impact of the pandemic on WLL utilization. Methods: Using data from the National Inpatient Sample from 2017 to 2021, the authors identified PAP, other diagnoses, and procedures. using the respective ICD-10 codes. Statistical analysis was performed on the trends of whole lung lavage and other outcomes across the five years. Results: A total of 3,030 hospitalized PAP patients were included in the study, with demographic and clinical characteristics reported for the cohort. Although the use of WLL increased from 11.55% pre-pandemic to 14.67% during the pandemic, this difference was not statistically significant. However, there was a significant rise in the incidence of acute respiratory failure during the pandemic (35.7% vs. 45.78%, p = 0.02). While transbronchial lung biopsies increased and open lung biopsies declined, these trends were not statistically significant. Conclusion: In recent years, despite a decline in the use of WLL for treating PAP and open lung biopsies for diagnosis, the rates have risen due to the impact of the COVID-19 pandemic.
Optimizing Bridge-to-Transplant MCS Strategies: Pre-transplant Predictors for ECMO and Impella Use in Heart Transplant Candidates
SAHAJWANI, JUHI , Bhusal, S. , Karki, Dhan Bahadur , Chaudhary, S., Chaudhary, A., Karki, D., Bhattacharyya, Anirban

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1812-A1812

10.1164/ajrccm.2025.211.abstracts.a1812 Get It

Abstract Rationale: Mechanical circulatory support (MCS) devices, including Extracorporeal Membrane Oxygenation (ECMO) and Impella are essential in managing complex heart transplant cases. Identifying predictors for MCS utilization can improve patient selection and perioperative planning. This study aims to refine MCS allocation by analyzing pre-transplant predictors for each device, thereby optimizing clinical decision-making in critical care. Methods: This retrospective study included 594 heart transplant patients from 2019-2024 (mean age: 63 ± 1.41 years, 29% female, mean left ventricular ejection fraction (LVEF): 36.5 ± 33.23%, mean body mass index (BMI): 32.23 ± 4.497 kg/m²). Variables assessed included age, gender, BMI, smoking status, comorbidities (e.g., chronic kidney disease, hypertension, diabetes), heart failure etiology, and hemodynamic parameters (cardiac index, LVEF, PAPi). Multivariate logistic regression models estimated odds ratios (OR) and 95% confidence intervals (CI) for the likelihood of ECMO and Impella use based on pre-transplant variables. Results: 1. ECMO Use: ECMO was significantly associated with younger age (<40 years), elevated pulmonary artery pressure (PAPi <1.5; OR = 2.70, 95% CI: 1.13-6.48), and reduced cardiac index (<2.2 L/min/m²; OR = 3.12, 95% CI: 1.50-6.49). Male patients also had a higher likelihood of ECMO requirement (OR = 0.54, 95% CI: 0.29-1.00). These findings suggest ECMO may be required for younger, hemodynamically compromised patients. 2. Impella Use: Impella use was significantly associated with smoking history (OR = 3.72, 95% CI: 1.71-8.58), hypertension (OR = 2.08, 95% CI: 1.02-4.43), and low baseline LVEF (<25%; OR = 2.20, 95% CI: 1.18-4.07). Patients with chronic kidney disease or diabetes also had increased odds of requiring Impella, indicating its relevance for high-risk patients with vascular or metabolic burdens. Conclusions: This study identifies distinct pre-transplant predictors that influence MCS allocation in heart transplant patients. ECMO is associated with younger age and lower cardiac index, while Impella is more likely to be used in patients with vascular or metabolic comorbidities. These insights can enhance precision in MCS allocation, supporting optimal outcomes in critical care management.